Allegations Only · Settlements Not Yet Approved
This article describes a proposed class action and three proposed partial settlements. The allegations in the lawsuit are unproven. The settling defendants — Purdue Canada, Valeant/Bausch and Mylan — deny the allegations, and there has been no judicial determination of liability. The settlements are not admissions of wrongdoing and have not yet been approved by the court.
This page is informational and is not legal advice. There is no claim form at this stage and nothing to submit to OpenClassActions.com.
Canada's national opioid class action is not over. The plaintiffs have reached three proposed partial settlements worth a combined CAD $29.3 million — but the agreements still need a judge's approval, there is no claim form yet, and the case presses on against the pharmaceutical companies that have not settled. This is a Canada-only proceeding: the settlement classes cover people in Canada, so U.S. residents are not eligible.
What Is This About?
The national Canadian opioid class action, Gebien et al. v. Apotex et al. (Court File No. CV-19-00620048-00CP), is a proposed class action in the Ontario Superior Court of Justice. The plaintiffs allege that opioid manufacturers expanded the prescription-opioid market by promoting a new narrative about opioid use beginning in the 1990s, and that people who took those products developed opioid use disorder. The case is led by class counsel Koskie Minsky LLP.In March 2026, the plaintiffs announced that they had reached three separate proposed partial settlements — with Purdue Canada, with Valeant/Bausch, and with Mylan — together worth CAD $29.3 million. These are proposed settlements: they do not take effect unless and until the court approves them at a hearing set for September 16, 2026. The lawsuit otherwise continues as a proposed class action against the remaining, non-settling defendants. Nothing on this page is a claim form, and there is currently nothing to file.
What Happened in the Canadian Opioid Class Action?
The proceeding was commenced in May 2019 against a large group of pharmaceutical manufacturers and distributors. As originally framed, the lawsuit sought more than CAD $1 billion in damages on behalf of people across Canada who were prescribed opioids and developed opioid use disorder. The Ontario court divided the certification process into phases to work through the threshold legal questions before reaching the merits.In a December 2023 phase-one decision, Justice Perell ruled that certain proposed causes of action could advance to the next certification phase, provided the plaintiffs identified appropriate representative plaintiffs with claims against the relevant manufacturers. The potentially viable claims the court allowed to proceed included breach of the Competition Act, negligent misrepresentation, fraudulent misrepresentation or deceit, and negligence based on an alleged failure to warn. The plaintiffs then filed a Second Fresh as Amended Statement of Claim on April 30, 2024, adding six proposed representative plaintiffs so that the operative complaint identifies seven in total, each of whom allegedly consumed opioid products made by one or more defendants and developed opioid use disorder.
It is important to be precise about where the case stands. The national action has not been fully certified, and it is not over. The proposed settlements involve certification for settlement purposes as against the three settling defendants, while the merits and the broader certification proceedings against the non-settling defendants continue.
Proposed Settlements Total $29.3 Million
The plaintiffs reached three separate proposed partial settlements. Each amount below is an all-inclusive gross figure, and in each case the settling defendant denies the allegations with no judicial determination of liability:Purdue Canada — Purdue Pharma Inc. and Purdue Frederick Inc., collectively described as Purdue Canada, have agreed to a proposed settlement of CAD $28.5 million.
Valeant/Bausch — Valeant Canada LP/Valeant Canada S.E.C. and Bausch Health Companies Inc. have agreed to a proposed settlement of CAD $600,000.
Mylan — Mylan Pharmaceuticals ULC has agreed to a proposed settlement of CAD $200,000.
Added together, CAD $28,500,000 + CAD $600,000 + CAD $200,000 comes to CAD $29,300,000. That $29.3 million is the combined gross settlement amount — not the sum that will necessarily be distributed directly to class members. Court-approved legal fees, notice and administration expenses, litigation funding obligations and other approved costs may be deducted before any distribution. Because there is no approved distribution protocol yet, it is not possible to estimate an individual payment, and this page does not attempt to.
Can Canadians File a Claim Now?
No. There is no claim form available at this stage, and no claim deadline has been announced. The settlements still require court approval at the September 16, 2026 hearing. Class counsel has stated that it intends to seek approval of a distribution plan and to provide information about eligibility and the claims process later in 2026 if the settlements are approved.Until that happens, there is nothing to file and no money to collect. OpenClassActions.com does not collect claim information, and you should not send personal details to us or to anyone presenting themselves as running a claims process for this case before an official process is announced.
Who May Be Included?
The three settlements do not share a single class definition — each has its own class and its own exclusions, set out in the court-authorized notices. In broad terms, each describes a class of people in Canada (subject to exclusions) who were prescribed or consumed the covered products of that settling defendant, together with qualifying heirs and family-law claimants.Purdue settlement. The Purdue notice generally describes a settlement class of people in Canada, subject to exclusions, who were prescribed or consumed covered Purdue products, along with qualifying heirs and family-law claimants. Notable exclusions include people whose only covered prescriptions were OxyContin or OxyNEO in Canada between January 1, 1996 and February 28, 2017; people who were not prescribed any other covered product during the relevant class period; officers or directors of the defendants; and members of the Bourassa OxyContin/OxyNEO class action. That carve-out is deliberate: it helps prevent overlap with the older, already-approved OxyContin/OxyNEO settlement discussed below.
Mylan settlement. The Mylan notice describes a settlement class covering people in Canada except Quebec who were prescribed or consumed covered Mylan products, together with qualifying heirs and family-law claimants. Quebec residents are not included in the Mylan settlement class.
Valeant/Bausch settlement. The Valeant/Bausch class and the list of covered products are defined in the current Valeant long-form notice linked from the Koskie Minsky case page. Readers who want to know whether they fall within that class should rely on the current court-authorized notice rather than any earlier draft schedule, because the controlling terms are those in the current notice and the settlement agreement.
In every case, final eligibility will depend on the applicable settlement agreement, the court's orders, and the distribution protocol that has not yet been approved.
What Does the Lawsuit Allege?
The allegations belong to the plaintiffs and are unproven. According to the complaint, opioid manufacturers sought to expand the prescription-opioid market by promoting a new narrative about opioid use for chronic conditions beginning in the 1990s. The plaintiffs allege that the defendants promoted prescription opioids for chronic pain and other conditions; minimized, obscured or inadequately disclosed addiction risks; made negligent or fraudulent misrepresentations; failed to provide adequate warnings to patients and healthcare professionals; and engaged in conduct that allegedly violated the Competition Act.The plaintiffs claim that the representative plaintiffs consumed opioid products manufactured by one or more defendants and, as a result, developed opioid use disorder. These statements are allegations that have not been tested at trial. The settling defendants deny the allegations, and the proposed settlements are not admissions of liability or wrongdoing.
September 16, 2026 Approval Hearing
The proposed settlements go before the Ontario Superior Court of Justice on September 16, 2026, at 10:00 a.m., at 330 University Avenue in Toronto. At that hearing the court will decide whether to approve the three proposed partial settlements as fair, reasonable and in the best interests of the settlement classes. Until the court grants approval, the settlements are not in effect.The deadline for class members to object to, or opt out of, these proposed settlements was May 4, 2026, and that deadline has already passed. If the court approves the settlements, class counsel has indicated that a distribution protocol, eligibility standards and claim instructions are expected later in 2026. That is the point at which any claims process would open — not before.
Important June 23, 2026 Limitation-Period Update
Separately from the settlements, class counsel reports that the court permitted the action to be discontinued against three companies: Ranbaxy Pharmaceuticals Canada Inc., Sun Pharmaceutical Industries Ltd., and Joddes Limited. The discontinuance is reflected in a February 2026 court order.According to the current case page, people who were prescribed and consumed opioids manufactured by the Ranbaxy defendants — and no other opioids — should be aware that the limitation period for starting an individual claim against those defendants resumes running on June 23, 2026. The same notice states that the limitation period for individual claims against Joddes also resumes running on June 23, 2026.
To be precise about what that date means: June 23, 2026 is not a settlement claim deadline. It is the date on which a previously suspended limitation period resumes running. A limitation period is the legal time window within which a person must start a claim. Because that window is governed by law and depends on each person's own circumstances, this article does not calculate how much time any individual has left. Anyone who thinks they may be affected may wish to obtain advice from a qualified Canadian lawyer promptly. This is general legal information, not legal advice.
Is This the Same as the Old OxyContin Settlement?
No. The older OxyContin/OxyNEO settlement is a separate, already-approved Canada-wide settlement of approximately CAD $20 million. It covered qualifying people who were prescribed and ingested OxyContin and/or OxyNEO between January 1, 1996 and February 28, 2017. Its claim deadline passed on June 27, 2024; claims have been under review and decision notices have been issued. You cannot file a new claim in that settlement. As noted above, the Purdue settlement in the Gebien case is drafted to exclude that earlier OxyContin/OxyNEO group precisely to avoid double recovery.Is This the Same as the Quebec Opioid Settlement?
No. The Quebec Opioid Class Action is a separate Quebec proceeding with its own active claims process and a claim deadline of July 31, 2026. The Quebec claim form is not the claim form for the national Gebien v. Apotex case, and the two should not be confused. If you are a Quebec resident, the Quebec proceeding — administered separately — is the process that may currently apply to you; the national Gebien settlements have no open claims process yet.What Happens Next?
The next milestone is the September 16, 2026 approval hearing. If the court approves the three proposed partial settlements, class counsel is expected to return to court later in 2026 with a proposed distribution protocol that would set the eligibility standards and the claims process. Only at that point would there be a claim form, a claim deadline, and information about how any money is to be allocated.Meanwhile, the proposed class action continues against the non-settling pharmaceutical defendants, and the broader certification proceedings on the merits remain ongoing. In short: the national Canadian opioid class action is not finished. Three proposed partial settlements totaling CAD $29.3 million await court approval on September 16, 2026, no claim form is currently available, and the litigation continues against other defendants. OpenClassActions.com will update this page as the case develops.
A Note on the Broader Opioid Crisis
For context on scale: the Public Health Agency of Canada has reported 5,608 opioid-related deaths in 2025, an average of roughly 15 per day. That figure reflects the contemporary opioid toxicity crisis as a whole, and current data shows that a substantial share of those harms involve the illegal or non-pharmaceutical drug supply, including fentanyl. It should not be read as a measure of harm caused by the defendants, their prescription products, or the specific conduct alleged in this lawsuit.Frequently Asked Questions
Is the Canada opioid class action finished?
No. The national class action, Gebien et al. v. Apotex et al., is not finished. The plaintiffs have reached three proposed partial settlements with Purdue Canada, Valeant/Bausch and Mylan, but those agreements still require court approval at a hearing scheduled for September 16, 2026. The lawsuit also continues as a proposed class action against the non-settling pharmaceutical defendants.
How much are the proposed settlements?
The three proposed partial settlements total CAD $29.3 million: CAD $28.5 million from Purdue Canada, CAD $600,000 from Valeant/Bausch, and CAD $200,000 from Mylan. Each figure is an all-inclusive gross amount. This is the combined gross settlement amount, not the sum that will necessarily be distributed to class members. Court-approved legal fees, notice and administration costs, litigation funding obligations and other approved expenses may be deducted.
Can I file a claim now?
No. There is no claim form available at this stage, and no claim deadline has been announced. The settlements still require court approval. Class counsel, Koskie Minsky LLP, has stated that it intends to seek approval of a distribution plan and to provide information about eligibility and the claims process later in 2026 if the settlements are approved.
When is the settlement approval hearing?
The settlement approval hearing is scheduled for September 16, 2026, at 10:00 a.m. before the Ontario Superior Court of Justice at 330 University Avenue in Toronto. At that hearing the court will decide whether to approve the proposed partial settlements. The settlements are not approved until the court orders it.
Who may qualify for compensation?
Each settlement has its own class definition. In general terms, the settlements describe classes of people in Canada — subject to exclusions — who were prescribed or consumed the covered products of the settling defendant, along with qualifying heirs and family-law claimants. The Mylan class covers people in Canada except Quebec. The Purdue class excludes people whose only covered prescriptions were OxyContin or OxyNEO between January 1, 1996 and February 28, 2017, and members of the Bourassa class action. Final eligibility will depend on the applicable settlement agreement, court orders and the future distribution protocol.
Is this the same as the OxyContin/OxyNEO settlement?
No. The older OxyContin/OxyNEO settlement is a separate, already-approved Canada-wide settlement of roughly CAD $20 million covering qualifying people prescribed and ingesting OxyContin and/or OxyNEO between January 1, 1996 and February 28, 2017. Its claim deadline passed on June 27, 2024, and claims are being reviewed. You cannot file a new claim in that settlement. The Purdue settlement in the Gebien case is deliberately drafted to exclude that earlier OxyContin/OxyNEO group to avoid overlap.
Does the settlement include Quebec residents?
The Mylan settlement class covers people in Canada except Quebec. There is also a separate Quebec Opioid Class Action with its own active claims process and a claim deadline of July 31, 2026; that Quebec claim form is not the claim form for the national Gebien case. Whether Quebec residents are included in the Purdue and Valeant/Bausch settlements depends on each settlement's class definition, which is set out in the court-authorized notices.
What happens to the claims against other pharmaceutical companies?
The proposed settlements are partial — they resolve the claims only against Purdue Canada, Valeant/Bausch and Mylan. The agreements permit the litigation to continue against the non-settling pharmaceutical defendants, and the broader certification proceedings on the merits remain ongoing.
Official Sources
- Koskie Minsky LLP — Liability for the Opioid Epidemic (case page & current updates)
- Purdue Canada long-form notice of certification and settlement approval hearing
- Mylan long-form notice of certification and settlement approval hearing
- Purdue Canada signed settlement agreement
- Valeant/Bausch signed settlement agreement
- December 2023 certification phase-one decision (Perell J.)
- Second Fresh as Amended Statement of Claim (filed April 30, 2024)
- February 23, 2026 Ranbaxy/Joddes discontinuance order
- Older OxyContin/OxyNEO settlement website (separate, closed to new claims)
- Quebec Opioid Class Action administrator page (separate proceeding)
- Public Health Agency of Canada — latest national data on substance-related harms (June 2026)
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
